Get the Stockscreener App
0.556
1.10%
-0.0062
After Hours:
.56
0.004
+0.72%
Citius Oncology Inc stock is traded at $0.556, with a volume of 32,600.
It is down -1.10% in the last 24 hours and down -10.32% over the past month.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
See More
Previous Close:
$0.5622
Open:
$0.53
24h Volume:
32,600
Relative Volume:
0.48
Market Cap:
$51.70M
Revenue:
$5.61M
Net Income/Loss:
$-42.51M
P/E Ratio:
-1.1931
EPS:
-0.466
Net Cash Flow:
$-16.86M
1W Performance:
-2.46%
1M Performance:
-10.32%
6M Performance:
-49.45%
1Y Performance:
-71.78%
1-Day Range:
$0.5125
$0.5898
1-Week Range:
$0.5125
$0.73
52-Week Range:
$0.4912
$2.37
Citius Oncology Inc Stock (CTOR) Company Profile
Name
Citius Oncology Inc
Sector
Phone
(908) 967-6677
Address
11 COMMERCE DRIVE, CRANFORD
Compare CTOR vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
0.556 | 52.27M | 5.61M | -42.51M | -16.86M | -0.466 |
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-25 | Upgrade | Maxim Group | Hold → Buy |
| Nov-27-24 | Initiated | Maxim Group | Buy |
Citius Oncology Inc Stock (CTOR) Latest News
Citius Oncology Inc (CTOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Citius Oncology, Inc. Revenue Breakdown – NASDAQ:CTOR - TradingView
TradingKey - TradingKey
Citius Oncology Inc (CTOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Citius Oncology Inc (CTOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CTOR|Citius Oncology Inc|Price:0.562|Chg%:-0.016 - TradingKey
Citius Oncology Inc (CTOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Citius Oncology Inc (CTOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CTOR|Citius Oncology Inc|Price:0.541|Chg%:-0.037 - TradingKey
Citius Oncology Inc (CTOR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Citius Pharmaceuticals (CTXR) Sidoti Micro-Cap Virtual Conference Summary - Quartr
Citius Oncology expands sales team for LYMPHIR launch - Investing.com
Citius Oncology expands sales team for LYMPHIR launch By Investing.com - Investing.com UK
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption - PR Newswire
Citius Oncology Inc. (CTOR) Q2 2026 Earnings: Significant EPS Miss with No Reported RevenueProfit Inflection Point - dars.gov.et
Citius Oncology (Nasdaq: CTOR) sets $18M stock deal at $1.09 to back LYMPHIR launch - Stock Titan
Citius Oncology (CTOR) Registration filing Summary - Quartr
CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
CTOR Q1 2026 Earnings: Significant EPS Miss Despite Stock RallyProfit Recovery Report - dars.gov.et
CTOR Q1 2026 Earnings: Significant EPS Miss Signals Ongoing Development-Stage ChallengesEarnings Yield Analysis - dars.gov.et
CTOR Q1 2026 Earnings: Significant EPS Miss as Pre-Revenue Company Posts Wider Than Expected LossOne-Time Gain Impact - dars.gov.et
Enterprise value to EBITDA forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Price to sales forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Citius Oncology, Inc. Actuals & Estimates (NASDAQ:CTOR) - TradingView
Citius Oncology, Inc. Actuals & Estimates (BOATS:CTOR) - TradingView
Price to earnings forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Citius Oncology Inc (CTOR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price to book forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
CTOR Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Citius Oncology (CTOR) Edges Higher as Shares Approach Resistance at $0.73Volume Rate Change - dars.gov.et
Citius Oncology Inc (CTOR) Valuation: PE, PB & Fair Value Analysis - TradingKey
CTOR Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin; No Revenue ReportedEPS Growth Rate - DonanımHaber
CITIUS ONCOLOGY INC (CTOR) Stock Chart - ChartMill
Citius Oncology Inc (CTOR) Institutional Confidence - TradingKey
CTOR Q1 2026 Earnings: Deep EPS Miss Highlights Pre‑Revenue ChallengesEstimate Revision Count - newsline.com
Citius Oncology Inc. (CTOR) Gains 6% as Buyers Defend Key SupportSentiment Divergence - newsline.com
Citius Oncology Inc. (CTOR) Edges Higher as Shares Test Key Resistance LevelsBox Spread - dars.gov.et
CTOR Q1 2026 Earnings: Significant EPS Miss Highlights Continued Investment in PipelineRevenue Surprise History - newsline.com
Citius Oncology (CTOR) Edges Higher as Stock Hovers Near SupportMcClellan Summation - newsline.com
[EFFECT] CITIUS ONCOLOGY, INC. SEC Filing - Stock Titan
Citius Oncology (CTOR) stake updated by majority holder Citius Pharma - Stock Titan
Citius Oncology, Inc. Financial Disclosures & SEC Filings - TradingView
[EFFECT] Citius Pharmaceuticals, Inc. SEC Filing - Stock Titan
Citius Oncology Reports Promising Phase 1 Results for LYMPHIR Plus Pembrolizumab in Recurrent Gynecologic Cancers at ASCO 2026 123 - Minichart
Citius Oncology Highlights Promising Phase 1 Results for LYMPHIR® Plus Pembrolizumab in Recurrent Gynecologic Cancers at ASCO 2026 123 - Minichart
Citius Highlights LYMPHIR Combo Data in Gynecologic Cancers - TipRanks
Citius Oncology (CTOR) registers 6.8M warrant shares; highlights Phase 1 LYMPHIR data - Stock Titan
Citius Oncology (NASDAQ: CTOR) highlights Phase 1 LYMPHIR plus pembrolizumab results - Stock Titan
Citius Oncology Highlights Phase 1 Data in an Investigator-Initi - GuruFocus
Citius Oncology (CTXR) Presents Promising Data on LYMPHIR for Gy - GuruFocus
Citius Oncology Inc Stock (CTOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.30%
2.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):